Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute

Table 1 Characteristics of 355 patients

Variables	Total (n = 355)	%
Age at brachyterapy (years) ^a	71 (48–83)
Initial PSA (ng/mL) ^a	7.11 (3.10–32.2)
Clinical T category
T1c	197	55%
T2a	128	36%
T2b or T2c	30	8%
D’Amico risk classification
Low	153	43%
Intermidiate	166	47%
High	36	10%
Gleason sum
6	206	58%
7	131	37%
8 or 9	18	5%
Hypertention
No	243	68%
Yes	112	32%
Diabetis
No	318	90%
Yes	37	10%
Pre-use of alpha-1 adrenoceptor antagonist
No	304	86%
Yes	51	14%
Baseline IPSS (0 to 35)
Continuous ^a	7 (0–33)
1 to 7	201	57%
8 to 19	130	37%
20 to 35	23	6%
Baseline OABSS (0 to 15)
Continuous ^a	3 (0–13)
0 to 5	289	81%
6 to 11	59	17%
12 to 15	4	1%
Prostate volume at diagnosis (mL) ^a	24.2 (7.8–59.9)
Prostate volume at implant (mL) ^a	25.7 (7.8–61.9)
Supplementary EBRT
No	247	70%
Yes	108	30%
Combined ADT
No	227	64%
Yes	128	36%
No of needles ^a	23 (14–36)
No of seeds ^a	60 (30–95)
BED (Gy2)	194.8 (120.3–253.2)

PSA prostate-specific antigen, IPSS International Prostate Symptom Score, OABSS overactive bladder symptom score, SD standard deviation, EBRT external beam radiotherapy, ADT androgen deprivation therapy, BED biologically effective dose
^a expressed by medians and ranges

ISSN: 1471-2490